(6-cyano-2,3,4,9-tetrahydro-1H-carbazol-3-yl)-carbamic acid tert-butyl ester | 147009-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (6-cyano-2,3,4,9-tetrahydro-1H-carbazol-3-yl)-carbamic acid tert-butyl ester
• 英文别名: 3-t-butyloxycarbonylamino-6-cyano-1,2,3,4-tetrahydrocarbazole；tert-butyl N-(6-cyano-2,3,4,9-tetrahydro-1H-carbazol-3-yl)carbamate
• CAS: 147009-19-6
• 化学式: C₁₈H₂₁N₃O₂
• 分子量: 311.384
• InChiKey: HZTXOKYBDOFKIR-UHFFFAOYSA-N

物化性质

• 沸点：
  524.5±50.0 °C(Predicted)
• 密度：
  1.23±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  77.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6-cyano-2,3,4,9-tetrahydro-1H-carbazol-3-yl)-carbamic acid tert-butyl ester 生成 tert-butyl N-(6-carbamoyl-2,3,4,9-tetrahydro-1H-carbazol-3-yl)carbamate
  参考文献：
  名称：

  Tetrahydrocarbazole derivatives for the manufacture of a medicament for the treatment of a disease where a 5-HT1-like agonist is indicated

  摘要：

  使用通式（I）的化合物，其中：R¹代表氢、卤素、三氟甲基、硝基、羟基、C₁₋₆烷基、C₁₋₆烷氧基、芳基C₁₋₆烷氧基、-CO₂R⁴、-(CH₂)nCN、-(CH₂)nCONR⁵R6、-(CH₂)nSO₂NR⁵R6、C₁₋₆烷酰胺基(CH₂)n或C₁₋₆烷基磺酰胺基(CH₂)n；R⁴代表氢、C₁₋₆烷基或芳基C₁₋₆烷基；R⁵和R⁶分别独立地代表氢或C₁₋₆烷基，或R⁵和R⁶与它们所连接的氮原子一起形成一个环；n代表0、1或2；而R²和R³分别独立地代表氢、C₁₋₆烷基或苯甲基，或与它们所连接的氮原子一起形成吡咯烷基、哌啶基或六氢杂环庚基；或其生理上可接受的盐，在制备治疗5-HT₁样受体激动剂适用的病症的药物方面使用，例如偏头痛。还描述了通式（I）的新化合物、制备它们的方法以及含有它们的制药组合物。

  公开号：

  EP0603432A1
• 作为产物：
  描述：

  N-(4-氧代环己基)酞酰亚胺 在 sodium acetate 、 一水合肼 、 溶剂黄146 作用下， 反应 2.0h， 生成 (6-cyano-2,3,4,9-tetrahydro-1H-carbazol-3-yl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  （+/-）3-氨基-6-羧酰胺基-1,2,3,4-四氢咔唑：5-羧酰胺基色胺的构象受限类似物，对5-羟色胺5-HT1D受体具有选择性。

  摘要：

  DOI：

  10.1021/jm00065a015

文献信息

• Use of tetrahydrocarbazone derivatives as 5HT.sub.1 receptor agonists
  申请人：SmithKline Beecham P.L.C.

  公开号：US05464864A1

  公开（公告）日：1995-11-07

  ##STR1## Use of a compound of general formula (I), wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl; or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  在制备治疗5-HT1-样受体激动剂适用的药物时，使用通式（I）的化合物，其中R^1代表氢、卤素、三氟甲基、硝基、羟基、C1-6烷基、C1-6烷氧基、芳基C1-6烷氧基、-CO2R^4、-(CH2)nCN、-(CH2)nCONR^5R^6、-(CH2)nSO2NR^5R^6、C1-6烷酰氨基(CH2)n或C1-6烷基磺酰氨基(CH2)n；R^4代表氢、C1-6烷基或芳基C1-6烷基；R^5和R^6分别独立表示氢或C1-6烷基，或R^5和R^6与其连接的氮原子一起形成环；n代表0、1或2；R^2和R^3分别独立表示氢、C1-6烷基；或苄基，或与其连接的氮原子一起形成吡咯啉、哌啶或六氢脲环；或其生理上可接受的盐，在制备这些化合物和含有它们的药物组合物的过程中也有描述。
• Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-HT.sub.1 agonist use
  申请人：Smithkline Beecham plc

  公开号：US05827871A1

  公开（公告）日：1998-10-27

  Use of a compound of general formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino(CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino(CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  将通用公式(I)的化合物用于制造药物，用于治疗需要5-HT1样受体激动剂的情况，例如偏头痛。公式(I)的新化合物、制备它们的方法以及含有它们的药物组成物也有描述。
• Enantiomers of carbazole derivatives as 5-HT.sub.1 -like agonists
  申请人：SmithKline Beecham plc

  公开号：US05616603A1

  公开（公告）日：1997-04-01

  A (+)or (-) enantiomer of a compound of formula (I) wherein R.sup.4 is methyl or ethyl, or a salt, solvate or hydrate thereof, processes for preparing said compounds and pharmaceutical compositions containing them. Compounds of formula (+) are 5-HT.sub.1 -like agonists.

  化合物公式（I）的A（+）或（-）对映体，其中R.sup.4是甲基或乙基，或其盐，溶剂合物或水合物，制备该化合物的方法以及含有它们的药物组合物。公式（+）的化合物是5-HT.sub.1-类似激动剂。
• Medicaments
  申请人：SmithKline Beecham p.l.c.

  公开号：US05637611A1

  公开（公告）日：1997-06-10

  Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described.

  使用一般式(I)的化合物：##STR1## 其中：R.sup.1代表氢，卤素，三氟甲基，硝基，羟基，C.sub.1-6烷基，C.sub.1-6烷氧基，芳基C.sub.1-6烷氧基，--CO.sub.2R.sup.4，--(CH.sub.2).sub.n CN，--(CH.sub.2).sub.n CONR.sup.5 R.sup.6，--(CH.sub.2).sub.n SO.sub.2NR.sup.5 R.sup.6，C.sub.1-6烷酰胺基(CH.sub.2).sub.n或C.sub.1-6烷基磺酰胺基(CH.sub.2).sub.n; R.sup.4代表氢，C.sub.1-6烷基或芳基C.sub.1-6烷基; R.sup.5和R.sup.6各自独立地代表氢或C.sub.1-6烷基，或R.sup.5和R.sup.6与它们连接的氮原子一起形成一个环; n代表0、1或2; R.sup.2和R.sup.3各自独立地代表氢、C.sub.1-6烷基或苄基，或者与它们连接的氮原子一起形成吡咯烷，哌啶或六氢噁唑环; 或其生理上可接受的盐，在制造治疗5-HT.sub.1样受体激动剂适用的情况下的药物中，例如偏头痛。还描述了公式(I)的新化合物、制备它们的过程和含有它们的药物组成物。
• TETRAHYDROCARBAZOLE DERIVATIVES USEFUL AS ANDROGEN RECEPTOR MODULATORS
  申请人：Fales Kevin Robert

  公开号：US20100022550A1

  公开（公告）日：2010-01-28

  The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of formula (I).

  本发明提供了以下公式的化合物：公式（I）或其药学上可接受的盐；包含有效量公式（I）化合物与适当载体、稀释剂或赋形剂的制剂；以及治疗生理障碍，特别是虚弱，骨质疏松，骨质疏松症和男女性功能障碍的方法，包括向需要的患者给予公式（I）化合物的有效量。